 This is a phase I, open-label, dose-escalation trial of defactinib VS-6063, a focal adhesion kinase inhibitor, in Japanese patients with non-hematologic malignancies. The purpose of this study is to assess the safety including the recommended phase 2 dose, the pharmacokinetics, and the anti-cancer activity of defactinib VS-6063. 